Detalhe da pesquisa
1.
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Mult Scler
; 28(10): 1591-1605, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35380078
2.
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Mult Scler
; 28(10): 1526-1540, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261318
3.
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
Mult Scler
; 27(14): 2219-2231, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33769117
4.
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Mult Scler
; 27(10): 1564-1576, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33205682
5.
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey.
J Med Internet Res
; 23(10): e29558, 2021 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34612826
6.
A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
J Med Internet Res
; 22(2): e16932, 2020 02 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32049062
7.
Learning ability correlates with brain atrophy and disability progression in RRMS.
J Neurol Neurosurg Psychiatry
; 90(1): 38-43, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30322898
8.
Predicting risk of secondary progression in multiple sclerosis: A nomogram.
Mult Scler
; 25(8): 1102-1112, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29911467
9.
Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
Mult Scler
; 23(5): 656-664, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27411701
10.
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Mult Scler
; 22(10): 1297-305, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26585439
11.
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
J Interferon Cytokine Res
; 43(6): 246-256, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36454249
12.
The effect of disease modifying therapies on fatigue in multiple sclerosis.
Mult Scler Relat Disord
; 79: 105065, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839365
13.
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
J Neurol
; 269(9): 5093-5104, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35639197
14.
A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm.
JMIR Med Inform
; 8(4): e17592, 2020 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32286236
15.
A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.
Mult Scler Relat Disord
; 38: 101861, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31865132